Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative
As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing...
Gespeichert in:
Veröffentlicht in: | Breast (Edinburgh) 2025-04, Vol.80, p.103887, Article 103887 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 103887 |
container_title | Breast (Edinburgh) |
container_volume | 80 |
creator | Henkel, Jan Laner, Andreas Locher, Melanie Wohlfrom, Tobias Neitzel, Birgit Becker, Kerstin Neuhann, Teresa Abicht, Angela Steinke-Lange, Verena Klink, Barbara Eichhorn, Birgit Schmidt, Winfried Berner, Daniel Teubert, Anna Holtorf, Anne Heinrich, Sarah Wildhardt, Gabriele Schulze, Martin von der Heyden, Laura Hörtnagel, Konstanze Steinberger, Daniela Kleier, Saskia Lorenz, Peter Glaubitz, Ralf Biskup, Saskia Holinski-Feder, Elke |
description | As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing laboratories vary, resulting in a different variant diagnostic rate. Therefore, we performed a retrospective NGS dataset analysis of suspected HBOC patients who had been tested at different German diagnostic laboratories that are part of the NASGE network.
We collected 29,317 HBOC datasets and compared the diagnostic yield applying the most common panel recommendations and an internal HBOC gene panel. Additionally, we analyzed the data concerning other potential tumor risk syndromes (TRS) not caused by pathogenic variants in the core panel genes.
At least one pathogenic variant causative for an autosomal-dominant TRS was identified in 4235 datasets, resulting in an overall diagnostic yield of 14.4 %. The diagnostic yield of pathogenic variants varied depending on the applied HBOC panel (between 5 and 26 genes) from 9.0 % to 13.8 % with the internal HBOC panel having a yield of 12.7 %. Notably, in about 1 % of cases, a pathogenic variant outside the established HBOC core genes was identified, indicating the presence of other TRS.
These results are consistent with previous observations that a significant proportion of patients with HBOC predisposition were not detected by the guideline-based gene panels and suggest that expanded diagnostics compared to currently recommended multigene panels may identify additional patients at high risk for developing cancer.
•Expanded gene panel testing for hereditary cancer increases the diagnostic yield.•Disease specific gene panels overlook 1 % of patients with a high-risk TRS.•Joint data analysis of different German diagnostic laboratories. |
doi_str_mv | 10.1016/j.breast.2025.103887 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3159798259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960977625000165</els_id><sourcerecordid>3159798259</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2027-24ec7d2e38ae494555e1c200a81fe7465271143c34d083015ae1e1bc7b14bdb63</originalsourceid><addsrcrecordid>eNp9UctuGyEURVGqxE3zB1XEMpU6LgwwwCZSYqVJq6hZtFkjBu7UWPNwALvKp_RvizVpl12B4DzuuQeh95QsKaHNp82yjWBTXtakFuWJKSWP0IIKVleMKHKMFkQ3pNJSNqfobUobQohmjTpBp0wrwRVRC_T76xTGjO1o-5cUEp46_BPi0IcRymWEHBz2NlvcxWnA0x4irvXHooSdTZDwr5DXOO3SFlwGj9cQwYds4wuepyvKvtBsDHYslNEVgcv7m8fVB2wT3tqYD5Z5Dfjb9fe7WxzGkIPNYQ_v0JvO9gnOX88z9PT59sfqvnp4vPuyun6oXAkuq5qDk74GpixwzYUQQMsPsYp2IHkjakkpZ45xTxQjVFigQFsnW8pb3zbsDF3Outs4Pe8gZTOE5KDv7QjTLhlGhZZa1UIXKJ-hLk4pRejMNoahhDWUmEMpZmPm2OZQiplLKbSLV4ddO4D_R_rbQgFczQAoOfcBokkuQNmVD7Hs1fgp_N_hD7ECntc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3159798259</pqid></control><display><type>article</type><title>Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative</title><source>DOAJ Directory of Open Access Journals</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Henkel, Jan ; Laner, Andreas ; Locher, Melanie ; Wohlfrom, Tobias ; Neitzel, Birgit ; Becker, Kerstin ; Neuhann, Teresa ; Abicht, Angela ; Steinke-Lange, Verena ; Klink, Barbara ; Eichhorn, Birgit ; Schmidt, Winfried ; Berner, Daniel ; Teubert, Anna ; Holtorf, Anne ; Heinrich, Sarah ; Wildhardt, Gabriele ; Schulze, Martin ; von der Heyden, Laura ; Hörtnagel, Konstanze ; Steinberger, Daniela ; Kleier, Saskia ; Lorenz, Peter ; Glaubitz, Ralf ; Biskup, Saskia ; Holinski-Feder, Elke</creator><creatorcontrib>Henkel, Jan ; Laner, Andreas ; Locher, Melanie ; Wohlfrom, Tobias ; Neitzel, Birgit ; Becker, Kerstin ; Neuhann, Teresa ; Abicht, Angela ; Steinke-Lange, Verena ; Klink, Barbara ; Eichhorn, Birgit ; Schmidt, Winfried ; Berner, Daniel ; Teubert, Anna ; Holtorf, Anne ; Heinrich, Sarah ; Wildhardt, Gabriele ; Schulze, Martin ; von der Heyden, Laura ; Hörtnagel, Konstanze ; Steinberger, Daniela ; Kleier, Saskia ; Lorenz, Peter ; Glaubitz, Ralf ; Biskup, Saskia ; Holinski-Feder, Elke</creatorcontrib><description>As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing laboratories vary, resulting in a different variant diagnostic rate. Therefore, we performed a retrospective NGS dataset analysis of suspected HBOC patients who had been tested at different German diagnostic laboratories that are part of the NASGE network.
We collected 29,317 HBOC datasets and compared the diagnostic yield applying the most common panel recommendations and an internal HBOC gene panel. Additionally, we analyzed the data concerning other potential tumor risk syndromes (TRS) not caused by pathogenic variants in the core panel genes.
At least one pathogenic variant causative for an autosomal-dominant TRS was identified in 4235 datasets, resulting in an overall diagnostic yield of 14.4 %. The diagnostic yield of pathogenic variants varied depending on the applied HBOC panel (between 5 and 26 genes) from 9.0 % to 13.8 % with the internal HBOC panel having a yield of 12.7 %. Notably, in about 1 % of cases, a pathogenic variant outside the established HBOC core genes was identified, indicating the presence of other TRS.
These results are consistent with previous observations that a significant proportion of patients with HBOC predisposition were not detected by the guideline-based gene panels and suggest that expanded diagnostics compared to currently recommended multigene panels may identify additional patients at high risk for developing cancer.
•Expanded gene panel testing for hereditary cancer increases the diagnostic yield.•Disease specific gene panels overlook 1 % of patients with a high-risk TRS.•Joint data analysis of different German diagnostic laboratories.</description><identifier>ISSN: 0960-9776</identifier><identifier>ISSN: 1532-3080</identifier><identifier>EISSN: 1532-3080</identifier><identifier>DOI: 10.1016/j.breast.2025.103887</identifier><identifier>PMID: 39854808</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Gene panel testing ; Genetic predisposition to disease ; Genetic testing ; Genetic variation ; Hereditary ; Hereditary breast and ovarian cancer syndrome ; High-throughput nucleotide sequencing ; Neoplastic syndromes ; Retrospective studies ; Risk assessment</subject><ispartof>Breast (Edinburgh), 2025-04, Vol.80, p.103887, Article 103887</ispartof><rights>2025 The Authors</rights><rights>Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2027-24ec7d2e38ae494555e1c200a81fe7465271143c34d083015ae1e1bc7b14bdb63</cites><orcidid>0000-0003-3798-5977</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0960977625000165$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39854808$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Henkel, Jan</creatorcontrib><creatorcontrib>Laner, Andreas</creatorcontrib><creatorcontrib>Locher, Melanie</creatorcontrib><creatorcontrib>Wohlfrom, Tobias</creatorcontrib><creatorcontrib>Neitzel, Birgit</creatorcontrib><creatorcontrib>Becker, Kerstin</creatorcontrib><creatorcontrib>Neuhann, Teresa</creatorcontrib><creatorcontrib>Abicht, Angela</creatorcontrib><creatorcontrib>Steinke-Lange, Verena</creatorcontrib><creatorcontrib>Klink, Barbara</creatorcontrib><creatorcontrib>Eichhorn, Birgit</creatorcontrib><creatorcontrib>Schmidt, Winfried</creatorcontrib><creatorcontrib>Berner, Daniel</creatorcontrib><creatorcontrib>Teubert, Anna</creatorcontrib><creatorcontrib>Holtorf, Anne</creatorcontrib><creatorcontrib>Heinrich, Sarah</creatorcontrib><creatorcontrib>Wildhardt, Gabriele</creatorcontrib><creatorcontrib>Schulze, Martin</creatorcontrib><creatorcontrib>von der Heyden, Laura</creatorcontrib><creatorcontrib>Hörtnagel, Konstanze</creatorcontrib><creatorcontrib>Steinberger, Daniela</creatorcontrib><creatorcontrib>Kleier, Saskia</creatorcontrib><creatorcontrib>Lorenz, Peter</creatorcontrib><creatorcontrib>Glaubitz, Ralf</creatorcontrib><creatorcontrib>Biskup, Saskia</creatorcontrib><creatorcontrib>Holinski-Feder, Elke</creatorcontrib><title>Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative</title><title>Breast (Edinburgh)</title><addtitle>Breast</addtitle><description>As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing laboratories vary, resulting in a different variant diagnostic rate. Therefore, we performed a retrospective NGS dataset analysis of suspected HBOC patients who had been tested at different German diagnostic laboratories that are part of the NASGE network.
We collected 29,317 HBOC datasets and compared the diagnostic yield applying the most common panel recommendations and an internal HBOC gene panel. Additionally, we analyzed the data concerning other potential tumor risk syndromes (TRS) not caused by pathogenic variants in the core panel genes.
At least one pathogenic variant causative for an autosomal-dominant TRS was identified in 4235 datasets, resulting in an overall diagnostic yield of 14.4 %. The diagnostic yield of pathogenic variants varied depending on the applied HBOC panel (between 5 and 26 genes) from 9.0 % to 13.8 % with the internal HBOC panel having a yield of 12.7 %. Notably, in about 1 % of cases, a pathogenic variant outside the established HBOC core genes was identified, indicating the presence of other TRS.
These results are consistent with previous observations that a significant proportion of patients with HBOC predisposition were not detected by the guideline-based gene panels and suggest that expanded diagnostics compared to currently recommended multigene panels may identify additional patients at high risk for developing cancer.
•Expanded gene panel testing for hereditary cancer increases the diagnostic yield.•Disease specific gene panels overlook 1 % of patients with a high-risk TRS.•Joint data analysis of different German diagnostic laboratories.</description><subject>Gene panel testing</subject><subject>Genetic predisposition to disease</subject><subject>Genetic testing</subject><subject>Genetic variation</subject><subject>Hereditary</subject><subject>Hereditary breast and ovarian cancer syndrome</subject><subject>High-throughput nucleotide sequencing</subject><subject>Neoplastic syndromes</subject><subject>Retrospective studies</subject><subject>Risk assessment</subject><issn>0960-9776</issn><issn>1532-3080</issn><issn>1532-3080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNp9UctuGyEURVGqxE3zB1XEMpU6LgwwwCZSYqVJq6hZtFkjBu7UWPNwALvKp_RvizVpl12B4DzuuQeh95QsKaHNp82yjWBTXtakFuWJKSWP0IIKVleMKHKMFkQ3pNJSNqfobUobQohmjTpBp0wrwRVRC_T76xTGjO1o-5cUEp46_BPi0IcRymWEHBz2NlvcxWnA0x4irvXHooSdTZDwr5DXOO3SFlwGj9cQwYds4wuepyvKvtBsDHYslNEVgcv7m8fVB2wT3tqYD5Z5Dfjb9fe7WxzGkIPNYQ_v0JvO9gnOX88z9PT59sfqvnp4vPuyun6oXAkuq5qDk74GpixwzYUQQMsPsYp2IHkjakkpZ45xTxQjVFigQFsnW8pb3zbsDF3Outs4Pe8gZTOE5KDv7QjTLhlGhZZa1UIXKJ-hLk4pRejMNoahhDWUmEMpZmPm2OZQiplLKbSLV4ddO4D_R_rbQgFczQAoOfcBokkuQNmVD7Hs1fgp_N_hD7ECntc</recordid><startdate>202504</startdate><enddate>202504</enddate><creator>Henkel, Jan</creator><creator>Laner, Andreas</creator><creator>Locher, Melanie</creator><creator>Wohlfrom, Tobias</creator><creator>Neitzel, Birgit</creator><creator>Becker, Kerstin</creator><creator>Neuhann, Teresa</creator><creator>Abicht, Angela</creator><creator>Steinke-Lange, Verena</creator><creator>Klink, Barbara</creator><creator>Eichhorn, Birgit</creator><creator>Schmidt, Winfried</creator><creator>Berner, Daniel</creator><creator>Teubert, Anna</creator><creator>Holtorf, Anne</creator><creator>Heinrich, Sarah</creator><creator>Wildhardt, Gabriele</creator><creator>Schulze, Martin</creator><creator>von der Heyden, Laura</creator><creator>Hörtnagel, Konstanze</creator><creator>Steinberger, Daniela</creator><creator>Kleier, Saskia</creator><creator>Lorenz, Peter</creator><creator>Glaubitz, Ralf</creator><creator>Biskup, Saskia</creator><creator>Holinski-Feder, Elke</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3798-5977</orcidid></search><sort><creationdate>202504</creationdate><title>Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative</title><author>Henkel, Jan ; Laner, Andreas ; Locher, Melanie ; Wohlfrom, Tobias ; Neitzel, Birgit ; Becker, Kerstin ; Neuhann, Teresa ; Abicht, Angela ; Steinke-Lange, Verena ; Klink, Barbara ; Eichhorn, Birgit ; Schmidt, Winfried ; Berner, Daniel ; Teubert, Anna ; Holtorf, Anne ; Heinrich, Sarah ; Wildhardt, Gabriele ; Schulze, Martin ; von der Heyden, Laura ; Hörtnagel, Konstanze ; Steinberger, Daniela ; Kleier, Saskia ; Lorenz, Peter ; Glaubitz, Ralf ; Biskup, Saskia ; Holinski-Feder, Elke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2027-24ec7d2e38ae494555e1c200a81fe7465271143c34d083015ae1e1bc7b14bdb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Gene panel testing</topic><topic>Genetic predisposition to disease</topic><topic>Genetic testing</topic><topic>Genetic variation</topic><topic>Hereditary</topic><topic>Hereditary breast and ovarian cancer syndrome</topic><topic>High-throughput nucleotide sequencing</topic><topic>Neoplastic syndromes</topic><topic>Retrospective studies</topic><topic>Risk assessment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henkel, Jan</creatorcontrib><creatorcontrib>Laner, Andreas</creatorcontrib><creatorcontrib>Locher, Melanie</creatorcontrib><creatorcontrib>Wohlfrom, Tobias</creatorcontrib><creatorcontrib>Neitzel, Birgit</creatorcontrib><creatorcontrib>Becker, Kerstin</creatorcontrib><creatorcontrib>Neuhann, Teresa</creatorcontrib><creatorcontrib>Abicht, Angela</creatorcontrib><creatorcontrib>Steinke-Lange, Verena</creatorcontrib><creatorcontrib>Klink, Barbara</creatorcontrib><creatorcontrib>Eichhorn, Birgit</creatorcontrib><creatorcontrib>Schmidt, Winfried</creatorcontrib><creatorcontrib>Berner, Daniel</creatorcontrib><creatorcontrib>Teubert, Anna</creatorcontrib><creatorcontrib>Holtorf, Anne</creatorcontrib><creatorcontrib>Heinrich, Sarah</creatorcontrib><creatorcontrib>Wildhardt, Gabriele</creatorcontrib><creatorcontrib>Schulze, Martin</creatorcontrib><creatorcontrib>von der Heyden, Laura</creatorcontrib><creatorcontrib>Hörtnagel, Konstanze</creatorcontrib><creatorcontrib>Steinberger, Daniela</creatorcontrib><creatorcontrib>Kleier, Saskia</creatorcontrib><creatorcontrib>Lorenz, Peter</creatorcontrib><creatorcontrib>Glaubitz, Ralf</creatorcontrib><creatorcontrib>Biskup, Saskia</creatorcontrib><creatorcontrib>Holinski-Feder, Elke</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henkel, Jan</au><au>Laner, Andreas</au><au>Locher, Melanie</au><au>Wohlfrom, Tobias</au><au>Neitzel, Birgit</au><au>Becker, Kerstin</au><au>Neuhann, Teresa</au><au>Abicht, Angela</au><au>Steinke-Lange, Verena</au><au>Klink, Barbara</au><au>Eichhorn, Birgit</au><au>Schmidt, Winfried</au><au>Berner, Daniel</au><au>Teubert, Anna</au><au>Holtorf, Anne</au><au>Heinrich, Sarah</au><au>Wildhardt, Gabriele</au><au>Schulze, Martin</au><au>von der Heyden, Laura</au><au>Hörtnagel, Konstanze</au><au>Steinberger, Daniela</au><au>Kleier, Saskia</au><au>Lorenz, Peter</au><au>Glaubitz, Ralf</au><au>Biskup, Saskia</au><au>Holinski-Feder, Elke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative</atitle><jtitle>Breast (Edinburgh)</jtitle><addtitle>Breast</addtitle><date>2025-04</date><risdate>2025</risdate><volume>80</volume><spage>103887</spage><pages>103887-</pages><artnum>103887</artnum><issn>0960-9776</issn><issn>1532-3080</issn><eissn>1532-3080</eissn><abstract>As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing laboratories vary, resulting in a different variant diagnostic rate. Therefore, we performed a retrospective NGS dataset analysis of suspected HBOC patients who had been tested at different German diagnostic laboratories that are part of the NASGE network.
We collected 29,317 HBOC datasets and compared the diagnostic yield applying the most common panel recommendations and an internal HBOC gene panel. Additionally, we analyzed the data concerning other potential tumor risk syndromes (TRS) not caused by pathogenic variants in the core panel genes.
At least one pathogenic variant causative for an autosomal-dominant TRS was identified in 4235 datasets, resulting in an overall diagnostic yield of 14.4 %. The diagnostic yield of pathogenic variants varied depending on the applied HBOC panel (between 5 and 26 genes) from 9.0 % to 13.8 % with the internal HBOC panel having a yield of 12.7 %. Notably, in about 1 % of cases, a pathogenic variant outside the established HBOC core genes was identified, indicating the presence of other TRS.
These results are consistent with previous observations that a significant proportion of patients with HBOC predisposition were not detected by the guideline-based gene panels and suggest that expanded diagnostics compared to currently recommended multigene panels may identify additional patients at high risk for developing cancer.
•Expanded gene panel testing for hereditary cancer increases the diagnostic yield.•Disease specific gene panels overlook 1 % of patients with a high-risk TRS.•Joint data analysis of different German diagnostic laboratories.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>39854808</pmid><doi>10.1016/j.breast.2025.103887</doi><orcidid>https://orcid.org/0000-0003-3798-5977</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0960-9776 |
ispartof | Breast (Edinburgh), 2025-04, Vol.80, p.103887, Article 103887 |
issn | 0960-9776 1532-3080 1532-3080 |
language | eng |
recordid | cdi_proquest_miscellaneous_3159798259 |
source | DOAJ Directory of Open Access Journals; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Gene panel testing Genetic predisposition to disease Genetic testing Genetic variation Hereditary Hereditary breast and ovarian cancer syndrome High-throughput nucleotide sequencing Neoplastic syndromes Retrospective studies Risk assessment |
title | Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T09%3A20%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Joint%20analysis%20of%20germline%20genetic%20data%20from%20over%2029,000%20cases%20with%20suspected%20hereditary%20breast%20and%20ovarian%20cancer%20(HBOC)%20as%20part%20of%20the%20NASGE%20initiative&rft.jtitle=Breast%20(Edinburgh)&rft.au=Henkel,%20Jan&rft.date=2025-04&rft.volume=80&rft.spage=103887&rft.pages=103887-&rft.artnum=103887&rft.issn=0960-9776&rft.eissn=1532-3080&rft_id=info:doi/10.1016/j.breast.2025.103887&rft_dat=%3Cproquest_cross%3E3159798259%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3159798259&rft_id=info:pmid/39854808&rft_els_id=S0960977625000165&rfr_iscdi=true |